Diffuse Large B Cell Lymphoma  >>  dexamethasone 
Welcome,         Profile    Billing    Logout  

9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
dexamethasone / Generic mfg.
NCT04442022 / 2020-000605-84: A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting
2/3
501
Europe, US, RoW
Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy)
Karyopharm Therapeutics Inc
Relapsed/Refractory Diffuse Large B-cell Lymphoma
12/24
12/25
2014-001620-29: Clinical trial to evaluate the treatment with a drug (lenalidomide) with the usually prescribed chemotherapy in patients diagnosed with diffuse large B-cell lymphoma (sort of blood cancer) which did not respond to previous treatments and who can not receive high-dose chemotherapy. Ensayo clínico para evaluar el tratamiento con un medicamento (lenalidomida) añadido a la quimioterapia utilizada habitualmente en pacientes con linfoma difuso de células grandes B (cáncer de la sangre) que no han respondido bien a tratamientos previos y que no pueden recibir quimioterapia a altas dosis

Ongoing
2
77
Europe
Lenalidomide, Rituximab, Gemcitabine, Cisplatin, NA, Capsule, hard, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Revlimid 5 mg, MabThera, Revlimid 10 mg, Revlimid 15 mg
Grupo Español para el Tratamiento y Estudio de los Linfomas (GOTEL), Grupo Español para el Tratamiento y Estudio de los Linfomas (GOTEL)
Refractory Diffuse large B-cell lymphoma. Linfoma difuso de células grandes B refractarios., Sort of cancer (Large B cells lymphoma) from specific haematological cells (from the blood). Tipo de cáncer (Linfoma de cálulas B grandes) que afecta a determinadas células hematológicas (de la sangre), Diseases [C] - Cancer [C04]
 
 
NCT05852717: Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma

Recruiting
2
32
US
AutoSCT OR CAR T-cell Therapy, Autologous transplant, chimeric antigen receptor (CAR) T-cell, GDP, Epcoritamab
Dipenkumar Modi, Genmab
Large Cell Lymphoma, Diffuse, Relapsed Cancer, Refractory Cancer
06/24
06/25
NCT05498220: Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting
2
44
US
Polatuzumab vedotin (PV), Rituximab, Hyaluronidase, Gemcitabine, Cisplatin, Dexamethasone, GCSF
UNC Lineberger Comprehensive Cancer Center, Genentech, Inc.
Diffuse Large B-cell Lymphoma
08/28
08/28
ARIA, NCT05205252: A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.

Calendar Jan 2023 - Dec 2024: Data from trial for hematological malignancies
Withdrawn
1b/2
156
US
Tazemetostat, IPN60200, Tafasitamab, Lenalidomide, Acalabrutinib, Bruton tyrosine kinase inhibitor, Daratumumab (Intravenously), Mosunetuzumab, Daratumumab (Subcutaneously), Hyaluronidase-Fihj, Pomalidomide, Dexamethasone 20mg
Epizyme, Inc.
Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy
07/23
07/23
ZUMA-1, NCT02348216 / 2015-005007-86: Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma

Checkmark Data from ZUMA-1 trial for R/R LBCL at ASH 2022
Dec 2022 - Dec 2022: Data from ZUMA-1 trial for R/R LBCL at ASH 2022
Checkmark Presentation from ZUMA-1 trial for DLBCL at ASTCT 2021
Feb 2021 - Feb 2021: Presentation from ZUMA-1 trial for DLBCL at ASTCT 2021
Checkmark Presentation from ZUMA-1 trial for DLBCL at ASH 2020
More
Completed
1/2
307
Europe, Canada, US, RoW
Axicabtagene Ciloleucel, Yescarta®, Fludarabine, Cyclophosphamide, Levetiracetam, Tocilizumab, Dexamethasone, High-dose methylprednisolone, Bendamustine, Rituximab, Doxorubicin, Prednisone, Vincristine, Ifosfamide, Carboplatin, Etoposide, Gemcitabine, Oxaliplatin, Cisplatin, Methylprednisolone
Kite, A Gilead Company
Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL), Primary Mediastinal B-cell Lymphoma (PMBCL), High Grade B-cell Lymphoma (HGBCL)
07/23
07/23
EPCORE NHL-2, NCT04663347 / 2020-000845-15: Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)

Checkmark Data from arm 6 of EPCORE NHL-2 trial for r/r/ follicular lymphoma at ASH 2022
Dec 2022 - Dec 2022: Data from arm 6 of EPCORE NHL-2 trial for r/r/ follicular lymphoma at ASH 2022
Checkmark Data from arm 2b of EPCORE NHL-2 trial for r/r follicular lymphoma at ASH 2022
Dec 2022 - Dec 2022: Data from arm 2b of EPCORE NHL-2 trial for r/r follicular lymphoma at ASH 2022
Checkmark Data from arm-4 of EPCORE NHL-2 trial for r/r DLBCL at ASH 2022
More
Recruiting
1/2
662
Europe, US, RoW
rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, R-CHOP, rituximab and lenalidomide, R2, rituximab and bendamustine, BR, rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin, R-DHAX/C, gemcitabine and oxaliplatin, GemOx, Epcoritamab, GEN3013, DuoBody®-CD3xCD20, EPKINLY™, rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone, R mini-CHOP, Lenalidomide, rituximab, ifosfamide, carboplatin, and etoposide phosphate, R-ICE
Genmab, AbbVie
Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
03/29
03/29
CCTG LY18-A, NCT04161248: Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

Recruiting
1
18
Canada
Venetoclax, Rituximab Injection, Rituximab SC, Gemcitabine, Dexamethasone, Cisplatin, Glofitamab, Tafasitamab
Canadian Cancer Trials Group, Roche Pharma AG, AbbVie, Incyte Corporation
Lymphoma, B-Cell
12/25
07/26
ChiCTR2000028715: A single arm study for doxorubicin hydrochloride liposome combined with lenalidomide, rituximab and dexamethasone in the treatment of elderly with diffuse large B-cell lymphoma

Not yet recruiting
N/A
30
 
doxorubicin hydrochloride liposome combined with lenalidomide, rituximab and dexamethasone
The Second Affiliated Hospital of Army Medical University; Xinqiao Hospital, National Nature Science Fund 81370594，National Nature Science Fund 81670100
lymphoma
 
 

Download Options